India's Dr Reddy's to manufacture Biosignal's furanones
Thursday, 20 January, 2005
Sydney-based Biosignal (ASX:BOS) has engaged Custom Pharmaceutical Serivces, a business unit of Indian generics-manufacturing specialist Dr Reddy's Laboratories, to develop a large-scale manufacturing procedure for Biosignal's antibacterial furanone compounds.
Dr Reddy's will then synthesise furanones for use in product development and registration Biosignal's anti-bacterial contact lenses and antifouling paints.
Custom Pharmaceutical Serivces produces cGMP compliant products in ISO certified facilities. Hyderabad-based Dr Reddy's is listed on the NYSE, and is best known for its aggressive pursuit of the generics market, launching numerous patent challenges against big pharma drugs. Its marketing rights for a generic version of Eli Lilly's Prozac ended two years ago. Dr Reddy's is also conducting research into new drugs.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
